(ZTS) Zoetis - Ratings and Ratios
Animal Medicine, Vaccines, Diagnostics, Pharmaceuticals, Biodevices
ZTS EPS (Earnings per Share)
ZTS Revenue
Description: ZTS Zoetis
Zoetis Inc. is a leading global animal health company that develops, manufactures, and commercializes a wide range of products and services for livestock and companion animals. The companys diverse portfolio includes medicines, vaccines, diagnostic products, and precision animal health products, which are marketed to veterinarians, livestock producers, and pet owners worldwide.
With a strong presence in the animal health industry, Zoetis has established itself as a key player in the development of innovative solutions for animal health. The companys products cater to various species, including cattle, swine, poultry, fish, sheep, dogs, cats, and horses. Its product offerings include parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, and animal health diagnostics, among others.
From a financial perspective, Zoetis has demonstrated strong performance, with a market capitalization of approximately $70.7 billion. The companys return on equity (ROE) stands at 51.32%, indicating a high level of profitability. Additionally, the price-to-earnings (P/E) ratio is around 28.49, suggesting that the stock may be slightly overvalued. However, the forward P/E ratio is lower at 25.06, indicating potential for future earnings growth.
Some key performance indicators (KPIs) to monitor for Zoetis include revenue growth, gross margin, and research and development (R&D) expenses as a percentage of sales. The companys R&D pipeline, including its collaboration with Blacksmith Medicines, Inc. to develop novel antibiotics, is also an important factor to watch. Furthermore, the trend of increasing pet ownership and the growing demand for animal health products and services are likely to drive Zoetis long-term growth prospects.
ZTS Stock Overview
| Market Cap in USD | 65,352m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2013-02-01 |
ZTS Stock Ratings
| Growth Rating | -32.3% |
| Fundamental | 89.1% |
| Dividend Rating | 62.9% |
| Return 12m vs S&P 500 | -35.9% |
| Analyst Rating | 4.26 of 5 |
ZTS Dividends
| Dividend Yield 12m | 1.24% |
| Yield on Cost 5y | 1.25% |
| Annual Growth 5y | 16.65% |
| Payout Consistency | 100.0% |
| Payout Ratio | 31.8% |
ZTS Growth Ratios
| Growth Correlation 3m | -45.7% |
| Growth Correlation 12m | -84.4% |
| Growth Correlation 5y | -3.7% |
| CAGR 5y | 0.06% |
| CAGR/Max DD 3y | 0.00 |
| CAGR/Mean DD 3y | 0.01 |
| Sharpe Ratio 12m | 0.41 |
| Alpha | 0.01 |
| Beta | 0.778 |
| Volatility | 25.01% |
| Current Volume | 1958.3k |
| Average Volume 20d | 2411.6k |
| Stop Loss | 142.5 (-3%) |
| Signal | -0.85 |
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income (2.61b TTM) > 0 and > 6% of Revenue (6% = 563.1m TTM) |
| FCFTA 0.15 (>2.0%) and ΔFCFTA 0.48pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 27.25% (prev 49.41%; Δ -22.17pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.20 (>3.0%) and CFO 2.93b > Net Income 2.61b (YES >=105%, WARN >=100%) |
| Net Debt (5.36b) to EBITDA (4.04b) ratio: 1.33 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.76 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (445.5m) change vs 12m ago -2.30% (target <= -2.0% for YES) |
| Gross Margin 70.03% (prev 68.32%; Δ 1.70pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 65.53% (prev 62.94%; Δ 2.59pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 15.18 (EBITDA TTM 4.04b / Interest Expense TTM 234.0m) >= 6 (WARN >= 3) |
Altman Z'' 7.05
| (A) 0.18 = (Total Current Assets 5.92b - Total Current Liabilities 3.37b) / Total Assets 14.48b |
| (B) 0.89 = Retained Earnings (Balance) 12.87b / Total Assets 14.48b |
| warn (B) unusual magnitude: 0.89 — check mapping/units |
| (C) 0.25 = EBIT TTM 3.55b / Avg Total Assets 14.32b |
| (D) 1.26 = Book Value of Equity 12.00b / Total Liabilities 9.50b |
| Total Rating: 7.05 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 89.09
| 1. Piotroski 8.50pt = 3.50 |
| 2. FCF Yield 3.15% = 1.57 |
| 3. FCF Margin 23.64% = 5.91 |
| 4. Debt/Equity 1.32 = 1.69 |
| 5. Debt/Ebitda 1.63 = 0.72 |
| 6. ROIC - WACC (= 16.50)% = 12.50 |
| 7. RoE 53.21% = 2.50 |
| 8. Rev. Trend 88.35% = 6.63 |
| 9. EPS Trend 81.56% = 4.08 |
What is the price of ZTS shares?
Over the past week, the price has changed by -1.67%, over one month by -3.54%, over three months by -8.81% and over the past year by -24.01%.
Is Zoetis a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ZTS is around 129.27 USD . This means that ZTS is currently overvalued and has a potential downside of -12.02%.
Is ZTS a buy, sell or hold?
- Strong Buy: 10
- Buy: 4
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ZTS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 190.1 | 29.4% |
| Analysts Target Price | 190.1 | 29.4% |
| ValueRay Target Price | 143.7 | -2.2% |
Last update: 2025-09-18 04:44
ZTS Fundamental Data Overview
CCE Cash And Equivalents = 1.44b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 25.3804
P/E Forward = 21.692
P/S = 6.9634
P/B = 13.023
P/EG = 2.1873
Beta = 0.887
Revenue TTM = 9.38b USD
EBIT TTM = 3.55b USD
EBITDA TTM = 4.04b USD
Long Term Debt = 5.23b USD (from longTermDebt, last quarter)
Short Term Debt = 1.35b USD (from shortTermDebt, last quarter)
Debt = 6.58b USD (Calculated: Short Term 1.35b + Long Term 5.23b)
Net Debt = 5.36b USD (from netDebt column, last quarter)
Enterprise Value = 70.50b USD (65.35b + Debt 6.58b - CCE 1.44b)
Interest Coverage Ratio = 15.18 (Ebit TTM 3.55b / Interest Expense TTM 234.0m)
FCF Yield = 3.15% (FCF TTM 2.22b / Enterprise Value 70.50b)
FCF Margin = 23.64% (FCF TTM 2.22b / Revenue TTM 9.38b)
Net Margin = 27.83% (Net Income TTM 2.61b / Revenue TTM 9.38b)
Gross Margin = 70.03% ((Revenue TTM 9.38b - Cost of Revenue TTM 2.81b) / Revenue TTM)
Tobins Q-Ratio = 5.87 (Enterprise Value 70.50b / Book Value Of Equity 12.00b)
Interest Expense / Debt = 0.88% (Interest Expense 58.0m / Debt 6.58b)
Taxrate = 20.33% (637.0m / 3.13b)
NOPAT = 2.83b (EBIT 3.55b * (1 - 20.33%))
Current Ratio = 1.76 (Total Current Assets 5.92b / Total Current Liabilities 3.37b)
Debt / Equity = 1.32 (Debt 6.58b / last Quarter total Stockholder Equity 4.98b)
Debt / EBITDA = 1.63 (Net Debt 5.36b / EBITDA 4.04b)
Debt / FCF = 2.97 (Debt 6.58b / FCF TTM 2.22b)
Total Stockholder Equity = 4.91b (last 4 quarters mean)
RoA = 18.04% (Net Income 2.61b, Total Assets 14.48b )
RoE = 53.21% (Net Income TTM 2.61b / Total Stockholder Equity 4.91b)
RoCE = 35.03% (Ebit 3.55b / (Equity 4.91b + L.T.Debt 5.23b))
RoIC = 24.64% (NOPAT 2.83b / Invested Capital 11.48b)
WACC = 8.14% (E(65.35b)/V(71.93b) * Re(8.89%)) + (D(6.58b)/V(71.93b) * Rd(0.88%) * (1-Tc(0.20)))
Shares Correlation 3-Years: -100.00 | Cagr: -0.47%
Discount Rate = 8.89% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 78.02% ; FCFE base≈2.17b ; Y1≈2.56b ; Y5≈3.92b
Fair Price DCF = 129.5 (DCF Value 57.37b / Shares Outstanding 443.2m; 5y FCF grow 18.89% → 3.0% )
EPS Correlation: 81.56 | EPS CAGR: 10.94% | SUE: 1.44 | # QB: 2
Revenue Correlation: 88.35 | Revenue CAGR: 7.78% | SUE: N/A | # QB: None
Additional Sources for ZTS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle